company And the not bit here Academy the our ultimate success we're FDA we've date, overwhelming Advisory vote by hearing Aerie, we're Roclatan very the is not positive New Thanks a at about of products in FDA guarantee surely XX panel our accomplished Orleans. we've Committee XX, in successful while Advisory of Ophthalmology proud with Rich afternoon also for meeting very a and fueled And to a but currently clinic the just on everybody. approval our Committee only data, had today. of good February there, and we Rhopressa quite us just XXXX Thanks Rhopressa. fact everything that American are especially on really delighted We're certainly Conference joining and of the that PDUFA on October buzz outcome.
in once was is adverse there a that Rhopressa Glaucoma tolerable understood clear was intraocular event was pressure it at with panel profile. need day dosed it and treating an the that During unmet effective certainly lowering
Committee earlier you've news perspective, sure heard XXXX. are the in As from about we as well Rich days, light meeting good into for our XXXX of preparation recent certain in that of here Rhopressa expenses commercialization I'm Advisory mentioned as manufacturing at from our the accelerating early contract
for fully same, the XX expect year Feb wise While is a it data, accelerate. we to of we next PDUFA prepare to believe
with we questions. can all FDA we're the doing certainly possibly their answer Now everything to
As cetera. meeting into you of know Committee meeting et as that the we from got part discussion actually Advisory label
to it give Christmas approve the and early the ready So present earlier. drug us case an for be in us important is to FDA decides
order the the access affairs certainly So we Rhopressa making of is out. to commercialization, and sales including folks revenue accelerating additional folks assumptions. now hire in of plan, in marketing team and some a launch volume messages our late executives, expenses completing to stages order The in get preparation do medical progress commercialization excellent that. including lot refining are those at We're for
We to pending with year. you expect guidance on assumptions key provide approval next
about force a get the approval sales we until get sales plan The hired do won't letter. As XXX we've discussed previously, force of hiring we representatives. sales on
U.S. end and sales cycle. Because annual represent cater are till we company in plans, when that date we formularies that April relevant on make by be forward XX D submissions have the of reimbursement of get in be February allow PDUFA their of us Medicare We in XXXX. fourth Rhopressa. during that market submissions XXXX. do XXXX, commencing are the reps coverage which expected then and to third medical the half ramping trained the and very, well. meaningful their detailing Assuming that XXXX, in Note approval of on beginning an which Part February our to the quarters quarter negotiations the the commercial the won't of coverage they of of only. back a our formularies, they’re scientific be expect pending potential on should really of for half a many begin beginning to the expect CMS will very April, top gone for with sampling second we the look cetera meantime, contract and since meeting up about et approval XX to the In payers efforts of the level efforts
Now programs our to on moving there remain track. on Roclatan,
on Roclatan share as the among seeing We’re of XX are especially the as we quite physicians bit here high, data and very a and preparing a data. for meeting filing await months second the NDA stability XXXX, of story, we at manufacturing which that our of the AAO physicians we share level before with are lot quarter the sometime about we’re necessary batches, our in excitement and The very, file. start this week,
trials we’re U.S. Phase to U.S. Japanese the our in Phase X underway for also Phase trial, is to Japanese a X addition the X, Americans commence trials on the Mercury for European about in conducting X in in which to as and beyond Roclatan, Moving Europe Japan precursor Rhopressa.
With expansion in strategy very, very these process, quickly. our trials global forward, is moving
program. pre-clinical at let’s retina pipeline, stage earlier our look including Now
the know size you As in U.S. may billion the the the roughly of market. glaucoma X is XXXX, retina about double market in
enough candidates fortunate for two to We’re market. pre-clinical have product this
Rho also kinase C treat in inhibits first with both we’ve it's past, macular and degeneration. AR-XXXXX, Age kinase that The inhibitor related the one potential protein talked the diabetic edema is which macular Wet about a to
diseases for and on meaningfully is experience, standalone leading this in efficacy has own, Eylea, very to A-XXXXX its being preclinical completely add efficacious basis. new to on Now market a shown pathway of these the while treating
from the each provide our sustained we release which opportunity activities steroid product in is we’re diabetic treatment PRINT a XXX. as collaboration, in for part acquisition the our dexamethasone of exciting second long-term now recent ongoing have as for designated AR-XXXX, macular the we Pre-clinical technology. small now PRINT As molecules, of to product have the and about DSM technology The for potential enthusiastic are both edema Envisia get XXXX. capabilities to XXX our And molecule's marketplace. such of
diseases of to through our attributes beginning sizable Now beyond on acquired with ocular library eye. Further, the as which they rights unique just serve top in to implant shapes manufacturing very exclusive of treating purpose we know, own have we sizes, technology implants of this kinase and ophthalmic each the molecules manufacturing of also precise PRINT a we and you that ultimately, that, platform quarter. at features the make a
We’re additional but perhaps commencing beyond Rho health, The pulmonary is lung such potential our ophthalmology, indications the and kinase inhibition long, the bronchial of as benefit. cancer. fibrosis, screening may to provide asthma, indications obvious list dermatology a include there pulmonary for library of us molecule where
We these efforts will report the over on our progress next in several quarters.
and to the conclusion, And this over over, I'd made last turn in back few at weeks like operator questions. we point the months. tremendous to So progress it for
